Glycome BioPharma is advancing its Pro‑Tects technology platform into one of the fastest‑growing segments of pharmaceutical packaging, the syringe plunger and vial stopper market.

The syringe plunger category is on a robust growth trajectory, propelled by the shift toward advanced drug delivery and higher standards demanded on pharmaceutical packaging. The market was valued at USD 1.42 billion in 2024, with a projected 9.1% CAGR, as manufacturers accelerate the move away from legacy materials toward next‑generation, more drug‑compatible and safe solutions.

“Industry has made its feelings clear on the risks of silicone and fluoropolymers, and we’re listening. That’s why we’re excited to announce this new market opportunity for our Pro‑Tects platform,” said Dr. Shane Smith, CEO of Glycome BioPharma. “By expanding our platform from drug containers into plungers and stoppers, we’re positioning Pro‑Tects to lead in safety across all primary packaging components.”